To include your compound in the COVID-19 Resource Center, submit it here.

Incyte and Hengrui end PD-1 mAb deal

Incyte Corp. (NASDAQ:INCY) said in an SEC document filed Feb. 15 that it

Read the full 135 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE